Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Left ventricular hypertrophy: should it be reduced?

F H Messerli1, F Soria, D Aristizabal

  • 1Department of Internal Medicine, Ochsner Clinic, New Orleans, LA 70121.

Clinical Cardiology
|May 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Individual Patient Data Validation of the EAU Definitions of BCG Failure in Patients with Non-muscle-invasive Urothelial Carcinoma of the Bladder: An International Multicenter Retrospective Study.

European urology oncology·2026
Same author

Impact of intravesical BCG Therapy on quality of life in non-muscle-invasive bladder cancer: a prospective evaluation using the FACT-Bl questionnaire.

Actas urologicas espanolas·2026
Same author

Efficacy and safety of active surveillance and chemoablation in the management of non-muscle invasive bladder cancer (NMIBC): Systematic review and pooled analysis by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group.

Actas urologicas espanolas·2026
Same author

Novel risk factors for venous thromboembolism following outpatient or inpatient transurethral resection of bladder tumors: Multivariable stepwise and LASSO regression modeling from us insurance claim database.

Actas urologicas espanolas·2025
Same author

Impact of opium on bladder cancer incidence: A systematic review and meta-analysis.

Actas urologicas espanolas·2025
Same author

Real-life perception of pathology reports in urology.

Actas urologicas espanolas·2025
Same journal

Comparing Ferric Carboxymaltose Versus Iron Sucrose in Patients with Heart Failure.

Clinical cardiology·2026
Same journal

Beyond Rural Versus Urban: Referral Pathways and Structural Heart Programs May Influence Outcomes After Left Atrial Appendage Occlusion.

Clinical cardiology·2026
Same journal

Strauss-Defined LBBB Identifies Patients With Improved Outcomes After CRT-D: A Comparative Cohort Study.

Clinical cardiology·2026
Same journal

Does Serum γKlotho Truly Provide Incremental Prognostic Value Beyond Established Risk Predictors in Multivessel Coronary Artery Disease?

Clinical cardiology·2026
Same journal

Associations of the C-Reactive Protein-Albumin-Lymphocyte Index, Red Cell Distribution Width-Albumin Ratio, and Blood Urea Nitrogen-Albumin Ratio With All-Cause and Cardiovascular Mortality Among Adults With Preclinical Heart Failure.

Clinical cardiology·2026
Same journal

Real-World National Databases Versus Hypothesis-Driven Cohort Studies: A Reply to the Critique on the TURK-HF Registry Design.

Clinical cardiology·2026
See all related articles

Left ventricular hypertrophy (LVH) is a heart condition linked to high blood pressure. ACE inhibitors effectively reduce LVH, improving heart function, but their impact on reducing cardiovascular death risk is still under investigation.

Area of Science:

  • Cardiology
  • Hypertension Research

Background:

  • Left ventricular hypertrophy (LVH) is a cardiac adaptation to hypertension.
  • LVH is an independent risk factor for cardiovascular events like heart attack and sudden death.
  • Pathophysiological consequences include impaired filling, contractility, arrhythmias, and ischemia.

Purpose of the Study:

  • To evaluate the impact of antihypertensive therapies on LVH.
  • To assess the efficacy of Angiotensin-Converting Enzyme (ACE) inhibition in reducing LVH.
  • To determine if LVH reduction improves associated pathophysiological sequelae.

Main Methods:

  • Review of recent clinical studies on LVH and antihypertensive treatments.
  • Analysis of the effects of different drug classes, particularly ACE inhibitors.

Related Experiment Videos

  • Evaluation of changes in left ventricular function and associated risks.

    • Main Results:

    • LVH is a significant predictor of cardiovascular morbidity and mortality.
    • ACE inhibition is a potent monotherapy for reducing LVH.
    • Reduction in LVH improves cardiac function and associated pathophysiological issues.

    Conclusions:

    • Antihypertensive therapy, especially ACE inhibition, can reduce LVH and improve cardiac function.
    • It is currently unknown if LVH reduction translates to decreased cardiovascular mortality.
    • Further research is needed to confirm the long-term benefits of LVH reversal on sudden death and heart failure risk.